Drugs / PG13-MAGE-A3 TCR9W11
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT01273181 | Dec 2010 → Dec 2012 | metastatic malignant neoplasm, metastatic melanoma, renal cell carcinoma | National Cancer Institute (NCI) | Terminated | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PG13-MAGE-A3 TCR9W11 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01273181 ↗ |
| Modality | Cell therapy | “adoptive cell therapy using autologous anti-MAGE-A3 T-cell receptors (TCR)-engineered T cells” PMID 23377668 ↗ Feb 2013 |
| Route | Intravenous | “intravenous infusion of ex vivo tumor reactive, TCR gene-transduced peripheral blood mononuclear cells (PBMC)” NCT01273181 ↗ |